Status:
COMPLETED
Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)
Lead Sponsor:
S.LAB (SOLOWAYS)
Collaborating Sponsors:
Center of New Medical Technologies
Triangel Scientific
Conditions:
Overweight and Obesity
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This randomized, double-blind, placebo-controlled trial titled "Preventing Weight Regain Post-Semaglutide Treatment with Active Fiber Supplement (Soloways)" evaluated the efficacy of an active fiber s...
Eligibility Criteria
Inclusion
- Adults with a history of obesity or overweight and completed Semaglutide course.
- Age 18-65 years.-
Exclusion
- Serious chronic illnesses.
- History of bulimia or anorexia.
- Pregnancy or lactation.
Key Trial Info
Start Date :
June 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT06221696
Start Date
June 12 2023
End Date
December 1 2023
Last Update
February 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center of New Medical Technologies
Novosibirsk, Novosibisk Region, Russia, 630090